Eyepoint Pharmaceuticals Inc (EYPT) — Cash Flow Reinvestment Rate

Latest as of June 2023: 0.25x

Eyepoint Pharmaceuticals Inc (EYPT) has a Cash Flow Reinvestment Rate of 0.25x as of June 2023, reinvesting $14.26 Million (capex $396.00K plus investments $13.86 Million) from operating cash flow of $57.02 Million. Explore Eyepoint Pharmaceuticals Inc capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.25x
(Capex + Investments) / Operating CF

Total Reinvested

$14.26 Million
Capex + Investments

Operating Cash Flow

$57.02 Million
USD

Capital Expenditures

$396.00K
USD

Eyepoint Pharmaceuticals Inc Cash Flow Reinvestment Rate (2010–2023)

Historical reinvestment intensity for Eyepoint Pharmaceuticals Inc across 3 annual periods. Also explore EYPT total assets for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Eyepoint Pharmaceuticals Inc (2010–2023)

Year-by-year capital reinvestment analysis for Eyepoint Pharmaceuticals Inc. For live market cap and broader valuation context, see Eyepoint Pharmaceuticals Inc (EYPT) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 3.63x $6.80 Million $1.88 Million $3.48 Million ▲ +727.8%
2015 0.44x $4.51 Million $10.30 Million $161.00K ▲ +28804.5%
2010 0.00x $15.00K $9.90 Million $15.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow